BOD Australia sees best day in 2-1/2 months as co starts medicinal cannabis trials

Bod Science

17/01/2022 02:12

** Shares of hemp healthcare products firm BOD Australia Ltd
 BDA.AX  gain as much as 6.8% to A$0.235, post their best
intraday session since Nov 5
    ** Co secures Clinical Trial Authorisation from the UK's
Medicines & Healthcare Products Regulatory Agency into medicinal
cannabis efficacy on COVID-19  urn:newsml:reuters.com:*:nASX8CjfKM
    ** Says six-month trials with UK's independent scientific
drug body, Drug Science UK, will explore the effectiveness of
the co's medicinal cannabis product on symptoms associated with
long-term impact of SARS-CoV-2
    ** Stock down 8.3% this year, as of last close

    
    

 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))